Major adverse cardiovascular events and mortality associated with ADHD and its treatment in adults with hypertension: a retrospective, multinational cohort study
The Lancet Primary Care · 2026-08 · 2 (8) · 100189
DOI: 10.1016/j.lanprc.2026.100189 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Lancet Primary Care, 2026-08. Verfasst von Yiling Zhou und 28 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Greater Copenhagen Health Science Partners, National Institute of Mental Health, Svenska Sällskapet för Medicinsk Forskning.
Abstract (Originalsprache)
Background
Adults with attention-deficit hyperactivity disorder (ADHD) have increased cardiometabolic risk. Hypertension increases the risk of major adverse cardiovascular events (MACE). We aimed to investigate whether ADHD is associated with MACE and all-cause mortality among adults with hypertension and assess medication safety among adults with ADHD and hypertension.
Methods
We conducted a retrospective, multinational cohort study across seven settings (Australia, England, Denmark, the Netherlands, Norway, Sweden, and the USA) using distributed network analyses with a common protocol. We included adults aged 18–90 years initiating first-line antihypertensive medications between Jan 1, 2010, and Dec 31, 2020 (depending on data availability); individuals with previous cardiovascular disease were excluded. Primary outcomes were incident MACE (composite of myocardial infarction, stroke, and cardiovascular death) and all-cause mortality. We estimated cause-specific hazard ratios (HRs) using Cox models with ADHD as a time-varying exposure. In a secondary analysis among adults with ADHD, we estimated HRs with ADHD medication use as a time-varying exposure. We pooled country-specific estimates using a random-effects meta-analysis.
Findings
Among 5 843 667 adults initiating first-line antihypertensives (2 980 617 [51·0%] were female and 2 863 050 [49·0%] were male; median follow-up ranged from 2·72 years [IQR 0·96–5·43] in the USA to 5·51 years [2·57–8·49] in Denmark), 113 397 (1·9%) had ADHD. Race and ethnicity data were not available. Unadjusted incidence rates among adults with and without ADHD were 9·8 (95% CI 9·5–10·2) per 1000 person-years and 11·1 (11·1–11·2) per 1000 person-years for MACE, and 8·6 (8·3–8·9) per 1000 person-years and 8·5 (8·4–8·5) per 1000 person-years for all-cause mortality, respectively. In pooled analyses, ADHD was associated with higher rates of MACE (HR 1·31 [95% CI 1·18–1·45]) and all-cause mortality (2·83 [2·07–3·87]) after adjusting for sex, age, and calendar year of first-line antihypertensive treatment initiation. In further controlled analyses, these associations attenuated after including psychiatric and cardiometabolic comorbidities and changed little after further including antihypertensive medication use during follow-up, indicating the relevance of comorbidity for prognosis. In pooled analyses among adults with ADHD, ADHD medication use was not associated with MACE (HR 1·00 [95% CI 0·85–1·17]) or all-cause mortality (0·96 [0·76–1·22]).
Interpretation
Among adults initiating antihypertensive treatment, ADHD marks a clinically vulnerable subgroup that might benefit from primary care combining routine hypertension care with adherence support and assessment and management of psychiatric and behavioural risk factors. Within the ADHD population, ADHD medication use was not associated with MACE, providing some reassurance regarding ADHD medication use in this population at increased cardiovascular risk under current clinical practice. Funding EU Horizon 2020 Research and Innovation Programme.
Förderung
- Greater Copenhagen Health Science Partners
- National Institute of Mental Health
- Svenska Sällskapet för Medicinsk Forskning
- Supernus Pharmaceuticals
- Savvaerksejer Jeppe Juhl og Hustru Ovita Juhls Mindelegat
- National Institutes of Health
- Jeanssons Stiftelser
- Upstate Foundation
Zitieren
APA
Zhou, Y., Dong, Z., Astrup, A., Engeland, A., Gillies, M. B., Lunde, A., Yuen, A. S. C., Zhang-James, Y., Araki, M., Brikell, I., Gao, L., Haavik, J., D’Onofrio, B. M., Sarsembayeva, D., Vos, M., Wimberley, T., Yao, H., Dalsgaard, S., Faraone, S. V., …, & Hartman, C. A. (2026). Major adverse cardiovascular events and mortality associated with ADHD and its treatment in adults with hypertension: a retrospective, multinational cohort study. The Lancet Primary Care, 2(8), 100189. https://doi.org/10.1016/j.lanprc.2026.100189
Vancouver
Zhou Y, Dong Z, Astrup A, Engeland A, Gillies MB, Lunde A, et al. Major adverse cardiovascular events and mortality associated with ADHD and its treatment in adults with hypertension: a retrospective, multinational cohort study. The Lancet Primary Care. 2026;2(8):100189. doi:10.1016/j.lanprc.2026.100189
BibTeX
@article{Zhou2026,
author = {Zhou, Yiling and Dong, Zihan and Astrup, Aske and Engeland, Anders and Gillies, Malcolm B and Lunde, Astrid and Yuen, Andrew S C and Zhang-James, Yanli and Araki, Masako and Brikell, Isabell and Gao, Le and Haavik, Jan and D’Onofrio, Brian M and Sarsembayeva, Dina and Vos, Melissa and Wimberley, Theresa and Yao, Honghui and Dalsgaard, Søren and Faraone, Stephen V and Klungsøyr, Kari and Larsson, Henrik and Man, Kenneth K C and Pearson, Sallie-Anne and Wong, Ian C K and Zoega, Helga and Chang, Zheng and Rietz, Ebba Du and Snieder, Harold and Hartman, Catharina A},
title = {Major adverse cardiovascular events and mortality associated with ADHD and its treatment in adults with hypertension: a retrospective, multinational cohort study},
journal = {The Lancet Primary Care},
year = {2026},
volume = {2},
number = {8},
pages = {100189},
doi = {10.1016/j.lanprc.2026.100189}
}
EUVIMED